Two New Promising  Cancer Fighters
Los Angeles, November 15, 2016. Bio Tech stocks are gaining momentum again.  In our never ending search for the next winner, we have dug up two new companies that are worthwhile taking a look at.

Novocure (NVCR) is marketing its FDA approved Optune system and is testing new products in five (5) stage II/III clinical and nine (9) pre-clinical trials. NVCR is currently trading at $9.05 and has  a BUY to STRONG BUY recommendation rating of 1.8 by four major analysts with a target price of $23.25.

Pfenex (PFNX) is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. The Company's initial focus is on biosimilar therapeutics and its lead product is PF582, a biosimilar to Lucentis (ranibizumab). PFNX is currently trading at $10.34 and has a a BUY recommendation rating of 1.8 by four major analysts with a target price of $20.00.

NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.

Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. Its lead product candidate is PF582, a biosimilar candidate to Lucentis that is in Phase 1b/2a trials in patients with wet age-related macular degeneration.  Its preclinical products under development consists of PF529 – peg-filgrastim, a biosimilar candidate to the reference product Neulasta; PF690 – pegaspargase, a biosimilar candidate to the reference product Oncaspar; PF726- peg-interferon beta for the treatment of relapsing multiple sclerosis; and PF444-human growth h. The company has collaboration agreement with Pfizer Inc. to develop PF582. Pfenex Inc. is headquartered in San Diego, California.
While we typically do not brag with "loud" headlines, but rather keep improving our services with ever improving research, w e would like to point out that since inception two years ago, our "SWI Portfolio" and our "SWI QuickPicks" have consistently outperformed all indices and many "Big-Firm" portfolios. We frequently provide you with performance reports for both portfolios to provide full transparency and provide you with a track record of our performance.
If you want to follow all other companies that we cover with more in depth research reports, go to our research site at to download the reports,
or visit for up to date news on the covered companies.
Please feel free to
re-distribute the Research Reports
and this Newsletter to your friends and colleagues.
Rainer Poertner - Chief Analyst
S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.  SWI has not been compensated for this report, may have acquired positions of stocks in this report for its portfolio a nd reserves the right to buy or sell positions at its sole  discretion. The included information is subject to change without notice. Please visit!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.